Clinical Trial

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

Name: MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma — clinical trial record (NCT07106736)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MAGIC-TIEMM

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a prospective, single-center, clinical study to evaluate the efficacy and safety of a fully immunotherapy-based strategy guided by MRD-driven dynamic risk stratification in transplant-ineligible patients with newly diagnosed multiple myeloma.

Trial Details

NCT Number	NCT07106736
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Multiple Myeloma, Newly Diagnosed
Enrollment	60 participants
Start Date	2025-08-10
Primary Completion	2027-08-01 (estimated)
Study Completion	2029-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-06